CAMBRIDGE, Mass. (
) -- Besides France's
, Genzyme's potential suitors might include
Johnson and Johnson
, a report says.
, the U.S. biotechnology company, became public Friday and Britain's GlaxoSmithKline and J&J are seen as the other most logical suitors for Genzyme, bankers and analysts said, according to the
Wall Street Journal
Glaxo recently made a very casual approach to Genzyme, telling executives there to keep Glaxo company in mind if Genzyme thought about selling itself, a person familiar with the matter told the
. But the contact ended there and there hasn't been continuing dialogue after the casual expression of interest, these people said.
Glaxo and and Johnson & Johnson declined to comment for the newspaper.
Genzyme had $4.5 billion in sales last year.
-- Written by Joseph Woelfel in New York.
Get more stock ideas and investing advice on our sister site,